← Back to Search

Practice facilitation for Human Papillomavirus (RAVE Trial)

N/A
Waitlist Available
Led By Lyle J Fagnan, MD
Research Sponsored by Oregon Health and Science University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

RAVE Trial Summary

This trial is testing interventions to get more HPV vaccinations in both male and female patients aged 9-26 years in rural areas.

Eligible Conditions
  • Human Papillomavirus

RAVE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
HPV vaccine series completion

RAVE Trial Design

5Treatment groups
Experimental Treatment
Group I: Practice Facilitation, Cluster 5Experimental Treatment1 Intervention
Intervention Cluster 5 is the final intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
Group II: Practice Facilitation, Cluster 4Experimental Treatment1 Intervention
Intervention Cluster 4 is the fourth intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
Group III: Practice Facilitation, Cluster 3Experimental Treatment1 Intervention
Intervention Cluster 3 is the third intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
Group IV: Practice Facilitation, Cluster 2Experimental Treatment1 Intervention
Intervention Cluster 2 is the second intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
Group V: Practice Facilitation, Cluster 1Experimental Treatment1 Intervention
Intervention Cluster 1 is the first intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.

Find a Location

Who is running the clinical trial?

Oregon Health and Science UniversityLead Sponsor
973 Previous Clinical Trials
7,363,812 Total Patients Enrolled
American Cancer Society, Inc.OTHER
224 Previous Clinical Trials
88,455 Total Patients Enrolled
Oregon Health AuthorityUNKNOWN
3 Previous Clinical Trials
2,218 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this clinical investigation accept participants at present?

"Per the information on clinicaltrials.gov, this trial is no longer enrolling patients as of March 17th 2022. The study was initially posted June 1st 2019 and has since been inactive; however, there are currently 89 other medical studies seeking participants."

Answered by AI

What is the eligibility criteria for this clinical experiment?

"To be eligible for this study, potential participants must have human papillomavirus and their age should lie between 18 and 89. In total, 22000 individuals are being recruited to take part in the trial."

Answered by AI

Does this trial permit the participation of minors?

"The prerequisites for this medical trial state that candidates must be between 18 and 89 years old. 19 trials are available to people younger than 18 and 54 for elderly persons above the age of 65."

Answered by AI
Recent research and studies
Cancer Prevention ResearchJournal
Reducing Hpv-associated Cancer Globally
Lowy, Douglas R., and John T. Schiller. 2012. “Reducing Hpv-associated Cancer Globally”. Cancer Prevention Research. American Association for Cancer Research (AACR). doi:10.1158/1940-6207.capr-11-0542.
Journal of Pediatric NursingJournal
Human Papillomavirus Infection and Vaccination
Valentino, Katie, and Cathlin B. Poronsky. 2016. “Human Papillomavirus Infection and Vaccination”. Journal of Pediatric Nursing. Elsevier BV. doi:10.1016/j.pedn.2015.10.005.
Current Opinion in PediatricsJournal
Adolescent Vaccinations
Mealey, Kathleen, and Laura M.P. Koenigs. 2019. “Adolescent Vaccinations”. Current Opinion in Pediatrics. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/mop.0000000000000759.
VaccineJournal
Acceptance of the HPV Vaccine Among Women, Parents, Community Leaders, and Healthcare Providers in Ohio Appalachia
Katz, Mira L., Paul L. Reiter, Sarah Heaner, Mack T. Ruffin, Douglas M. Post, and Electra D. Paskett. 2009. “Acceptance of the HPV Vaccine Among Women, Parents, Community Leaders, and Healthcare Providers in Ohio Appalachia”. Vaccine. Elsevier BV. doi:10.1016/j.vaccine.2009.04.040.
~3771 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top